Scientific, professional and academic training has developed around the field of internal medicine and hepatology. My interests initially focused on chronic cholestatic liver diseases of the adult (primary biliary cholangitis, primary sclerosing cholangitis), the liver disease complicating cystic fibrosis, and Wilson’s disease. Initial involvement in the assessment of litholytic use of bile acids for gallstone disease soon extended to study of the effectiveness of ursodeoxycholic acid and its conjugates in the treatment of chronic cholestatic diseases of sutoimmune origin and the treatment of cystic fibrosis-related liver disease. Within the context of the latter chronic conditions, I also got involved in the assessment of their natural history/clinical course and the identification of prognostic factors and markers conditioning the progression rate of disease. Research activity in this field led to publication of the first studies outlining the natural history of cystic fibrosis-related liver disease and the earliest demonstrations of the therapeutic efficacy of ursodeoxycholic acid treatment in cystic fibrosis and primary biliary cholangitis. Research interests then extended to treatment of HCV-related cirrhosis and, since 2009, to the natural history of NASH and the epidemiological investigation of the relationship between cardiovalscular risk factors/diabetes and metabolic liver disease in the general population.